ClinicalTrials.gg
Not yet recruitingNCT06961825NutristrokeUpdated May 8, 2025

Brief Title: The Role of Nutrition in the Rehabilitation of Patients With Eating Disorders After a Vascular Stroke.

An interventional study of Dietary Supplement in Stroke, Hypoalbuminemia and Sarcopenia, sponsored by University of Ioannina. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by University of Ioannina · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Stroke with a site in Greece — 13 open to participants now, 18 under way, 3 of them phase 3. Stroke · Greece.

Planned enrollment
32nd of 44
100 · median 920
Started
2025
with 4 others
No phase
19 of 55
10 open now
Primary completion
2030-05
later than 16 of 17 live
Registered
48th of 55
by date
Lead sponsor
4 of 55
University of Ioannina

Among the 55 studies in Stroke with a site in Greece, this one is the 32nd largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2025, is one of 19 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 48th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

13 of the 55 studies in Stroke with a site in Greece are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Stroke with a site in Greece, or all of them as a file.
02

Study summary

Brief Summary: The main objective of this thesis is to investigate the role of nutrition - specifically the administration of protein supplements (single dose and double dose) - in the rehabilitation of stroke patients with low albumin levels in relation to sarcopenia, osteopenia and functional recovery indices. The study will follow a randomized controlled trial design, incorporating clinical observation, analysis of biochemical markers, and assessment of physical and functional parameters. Participants will be randomly assigned to one of the three groups: (1) Group 1, receiving no protein supplementation (control group), (2) Group 2, receiving a single dose of protein supplement and (3) Group 3, receiving a double dose of protein supplement. The intervention will last for at least six weeks or until the biochemical markers of albumin normalize and the patient resumes regular oral intake. Biochemical assessment with be conducted through regular nutritional evaluations including measurement of serum albumin, prealbumin, C - reactive protein, creatinine, blood glucose and glycosylated hemoglobin (HbA1c), urea, electrolytes, urine albumin and additional inflammatory markers. Bone density will be assessed using DEXA, MBSR and hip measurements to determine the potential improvements resulting from the intervention. Muscle mass will be evaluated using whole - body DEXA analysis, while muscle strength and mobility will be assessed through grip strength tests and fine gait assessments. Functional recovery will be evaluated usings standardized tools for activities of daily living (Barthel Index), mental state (Geriatric Depression Scale) and quality of life (SF - 36), as well as mobility and walking tests such as the Timed Up and Go Test and 6 - Minute Walk Test. The collected data will be analyzed using appropriate statistical tools, including comparison models (ANOVA, Mann - Whitney U test) and correlation models (Pearson - Spearman). This research is expected to enhance theoretical knowledge regarding the relationship between nutrition, biochemical markers and rehabilitation outcomes in stroke patients with hypoalbuminemia. More specifically, it aims to explore the underlying mechanisms through which nutrition affects recovery - a field that remains unexplored. Additionally, the anticipated finding may contribute to the development of clinical guidelines and therapeutic approaches for the nutritional management of patients with low albumin levels, promoting personalized nutritional strategies that support effective post - stroke rehabilitation.

03

Conditions studied

  • Stroke
  • Hypoalbuminemia
  • Sarcopenia
  • Osteopenia
  • Malnutrition (Calorie)
  • Protein-energy Malnutrition
  • Functional Decline

Keywords

  • protein supplementation
  • nutritional intervention
  • albumin levels
  • stroke
  • stroke rehabilitation
  • eating disorders
  • malnutrition
  • nutritional assessment
  • sarcopenia
  • osteopenia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: Adults aged 18 to 85 years
  • Diagnosis: Patients diagnosed with a stroke (cerebrovascular accident) within the last 4 to 6 weeks
  • Serum albumin levels: Patients with low serum albumin levels (\< 3.5 g / dL)
  • Nutritional intervention requirement: Patients who require nutritional intervention to support rehabilitation and nutrition
  • : Patients who have completed the consent form for participation in the study and acceptance of the intervention

Exclusion criteria

Exclusion Criteria:

  • Severe infections or serious cardiopulmonary conditions: Patients with severe infections or serious cardiopulmonary conditions requiring immediate medical intervention, which may affect nutrition and rehabilitation
  • Comorbidities: Patients with comorbid conditions such as renal or liver disease
  • History of stroke or neurological conditions: Patients with a history of stroke or other neurological conditions who do not meet the criteria for rehabilitation
  • Severe mental or psychological conditions: Patients with severe mental or psychological conditions who are unable to understand or consent to participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Protein Supplement - Single Dose

    Participants in this arm will receive one dose of protein supplement daily.

    Dietary Supplement: Dietary Supplement

  • Experimental
    Protein Supplement - Double Dose

    Participants in this arm will receive two doses of protein supplement daily.

    Dietary Supplement: Dietary Supplement

  • No intervention
    Control group

    no protein supplementation

Interventions

  • Dietary supplementDietary Supplement

    complete, semi-elemental formula for tube feeding and orla intake based on peptides, in powder form, low in fat (32% of energy), high in MCTs (\>90% of total fat) free of fiber and gluten

06

What researchers measure

Primary outcomes

  1. Serum Albumin Levels

    Change in serum albumin concentration to assess nutritional status and response to protein supplementation.

    Time frame: Baseline and every 2 weeks for up to 6 weeks

Secondary outcomes

  1. Muscle Mass (Whole-body DEXA)

    Evaluation of changes in muscle mass using DEXA scan.

    Time frame: Baseline and at week 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for May 2030, 60 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 60 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 8, 2025
StartEst.
May 5, 2025
Primary completionEst.
May 5, 2030
CompletionEst.
May 5, 2030
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961825
Lead sponsor
University of Ioannina
Responsible party
Avraam Ploumis (Assistan Professor of PMR,Orthopaedic Spine Surgeon, University of Ioannina) — Principal investigator
First posted
May 8, 2025
Start date
May 5, 2025 (estimated)
Primary completion
May 5, 2030 (estimated)
Completion
May 5, 2030 (estimated)
Last update
May 8, 2025

Study contacts

ΑΒΡΑΑΜ Πλούμης
Contact
aploumis@uoi.gr
+306932080701
Avraam Ploumis
Contact
Avraam Ploumis
principal investigator · University Hospital, Ioannina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion